Patents by Inventor Daniela Della Ducata

Daniela Della Ducata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20210130451
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 6, 2021
    Applicant: MORPHOSYS AG
    Inventors: Stefan HARTLE, Stephane LECLAIR, Amgad SHEBL, Stefan STEIDL, Bodo BROCKS, Daniela Della DUCATA, Kai ROSPORT
  • Treatment for rheumatoid arthritis
    Patent number: 10913792
    Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 9, 2021
    Assignee: Morphosys AG
    Inventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
  • THERAPEUTIC ANTIBODIES BINDING IL 12RBETA1
    Publication number: 20140248265
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNy production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNy production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Application
    Filed: March 20, 2014
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Michael Otto BARDROFF, Jose M. CARBALLIDO HERRERA, Daniela DELLA DUCATA, Christoph HEUSSER, Ute JAEGER, Christoph SCHWAERZLER
  • Therapeutic antibodies binding IL12R?1
    Patent number: 8715657
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: May 6, 2014
    Assignee: Novartis AG
    Inventors: Michael Bardroff, Jose M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
  • IL-17A antibodies
    Patent number: 8519107
    Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: August 27, 2013
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu
  • COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES
    Publication number: 20120034231
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Application
    Filed: March 29, 2010
    Publication date: February 9, 2012
    Applicant: NOVARTIS AG
    Inventors: Michael Bardroff, José M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
  • IL-17A Antagonists
    Publication number: 20110236390
    Abstract: Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
    Type: Application
    Filed: October 29, 2010
    Publication date: September 29, 2011
    Inventors: Juan Carlos Almagro, Daniela Della Ducata, Merle Elloso, Jinquan Luo, Thomas Malia, Michael Naso, Galina Obmolova, Robert Rauchenberger, Mark Rutz, Raymond Sweet, Susann Taudte, Bingyuan Wu, Sheng-Jiun Wu